Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$24.40M
• Dividend Yield: N/A
• Average Volume (3M): 20.16K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.35
• Revenue Growth: 53.98%
• EPS Growth: -37.86%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 128,442,080
• 10 Day Avg. Volume: 12,708
• 30 Day Avg. Volume: 20,155
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 14.37
• Price to Cash Flow (P/CF): -21.10
• P/FCF Ratio: 78.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Rapid Dose Therapeutics Corp's overall score reflects severe financial challenges, including negative profitability and high leverage, which weigh heavily on the stock's potential. While recent corporate events signal efforts to improve financial stability and product offerings, the negative technical indicators and valuation metrics suggest caution. The company needs significant improvements in financial health and strategic execution to enhance its stock performance.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp (DOSE) is a Canadian biotechnology company that specializes in innovative drug delivery solutions. The company focuses on healthcare, nutraceutical, and pharmaceutical sectors, offering proprietary systems like QuickStrip™, an oral thin film that delivers active ingredients rapidly into the bloodstream, enhancing the efficacy and convenience of drug administration.

How the Company Makes Money

Rapid Dose Therapeutics Corp generates revenue primarily through the sale and licensing of its QuickStrip™ technology. The company partners with pharmaceutical, nutraceutical, and cannabis companies to incorporate QuickStrip™ into their product lines, earning income from manufacturing agreements and royalties. Additionally, Rapid Dose may engage in joint ventures or strategic collaborations to expand its application range and market penetration, further boosting its revenue streams.

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Rapid Dose Therapeutics Corp exhibits significant financial challenges with negative profitability, high leverage, and cash flow issues. Despite some revenue growth, the company's financial stability is compromised by consistent losses and a weak balance sheet. Urgent improvements in cost management and capital structure are necessary to stabilize financial health.

Income Statement

The company is struggling with profitability as evidenced by negative margins across the board. The TTM gross profit margin is -17.02%, highlighting the challenge in covering the cost of goods sold. Net profit margin is severely negative, indicating significant losses. Revenue growth rate is positive, showcasing some capability to increase sales, but this is overshadowed by persistent negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a highly leveraged position with a negative stockholders' equity, resulting in an undefined debt-to-equity ratio, which signals financial instability. The company has negative equity ratio and significant liabilities, posing a risk to financial stability and growth. Return on equity is not calculable due to negative equity, further indicating financial distress.

Cash Flow

Operating cash flow is negative, which is concerning as it reflects cash outflows from core operations. Free cash flow is also negative, indicating a lack of cash generated after capital expenses. The free cash flow growth rate is undefined due to negative values, and the ratios to net income are skewed by negative figures, highlighting liquidity concerns.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
1.61M	1.02M	718.30K	1.75M	262.81K	101.50K
	Gross Profit
-274.04K	563.41K	372.40K	1.34M	207.45K	37.34K
	EBIT
-2.97M	-3.74M	-3.54M	-4.30M	-2.13M	-7.51M
	EBITDA
-4.19M	-3.02M	-2.92M	-7.59M	-987.23K	-7.37M
	Net Income Common Stockholders
-5.78M	-4.31M	-3.81M	-12.55M	-2.44M	-8.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.17K	161.06K	27.59K	34.44K	70.26K	3.47K
	Total Assets
6.17K	1.89M	2.25M	3.07M	3.83M	4.29M
	Total Debt
0.00	2.45M	1.61M	1.17M	2.06M	1.22M
	Net Debt
-6.17K	2.29M	1.58M	1.14M	1.99M	1.22M
	Total Liabilities
10.42K	5.04M	4.92M	2.82M	5.41M	4.44M
	Stockholders Equity
-4.25K	-3.16M	-2.67M	251.56K	-1.58M	-147.78K
Cash Flow		Free Cash Flow
-2.31M	-2.29M	-863.92K	-3.04M	-1.63M	-4.26M
	Operating Cash Flow
-2.31M	-2.29M	-863.92K	-3.00M	-1.62M	-3.03M
	Investing Cash Flow
0.00	0.00	0.00	1.85M	-9.12K	530.46K
	Financing Cash Flow
2.18M	2.43M	856.53K	1.13M	1.65M	1.24M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.19, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.02 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	67 Neutral	C$350.07M	―	-3.15%	5.20%	-15.41%	-69.47%
HLS	52 Neutral	C$131.94M	―	-23.20%	―	-8.80%	26.77%
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
CCB	39 Underperform	C$3.63M	―	-11.71%	―	―	24.59%
DOSE	36 Underperform	C$24.40M	―	136.37%	―	53.98%	-37.86%
CRDL	32 Underperform	$100.78M	―	-138.82%	―	―	-18.03%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Therapeutics to Settle Debt with Share Issuance

Rapid Dose Therapeutics Corp. announced its plan to issue common shares to satisfy the quarterly interest on its secured convertible notes, with an expected issuance by April 11, 2025. The company will issue 463,716 common shares at $0.20 per share to cover $92,745.22 in accrued interest. Additionally, the company is working towards closing a Shares for Debt Transaction by April 24, 2025, which involves issuing up to 1,600,000 common shares to settle outstanding debts with creditors. This move is part of RDT’s ongoing financial strategy to manage its obligations and strengthen its market position.

Rapid Dose Therapeutics Announces $5 Million Equity Financing Plan

Rapid Dose Therapeutics Corp. announced a plan for an equity private placement financing to raise up to $5 million by issuing up to 20,833,333 common shares at $0.24 each. The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing involves Meadowbank Asset Management Inc. as the agent, who will receive a cash commission and warrants. This move is expected to strengthen RDT’s financial position, enabling further growth and development of its innovative drug delivery solutions.

Rapid Dose Therapeutics Expands Collaboration for 2025 Market-Ready Nicotine Product

Rapid Dose Therapeutics Corp. (RDT) has expanded its collaboration with an unnamed international company to advance the development of QuickStrip® Nicotine products, targeted for a 2025 market launch. This strategic partnership emphasizes RDT’s commitment to pioneering science-based, smoke-free alternatives, leveraging their unique Oral Thin Film (OTF) technology to meet global market demands and transition adult smokers to safer options.

Rapid Dose Therapeutics Updates Debt Settlement Strategy

Rapid Dose Therapeutics Corp announced an update on its debt settlement plan involving the issuance of up to 1,600,000 common shares to creditors in exchange for canceling $400,000 of outstanding accounts payable. Additionally, the company has decided not to proceed with a previously proposed private placement of up to $6,000,000. This move reflects a shift in the company’s financial strategy, potentially impacting its liquidity and market positioning.

Rapid Dose Therapeutics to Issue Shares for Quarterly Interest on Debt

Rapid Dose Therapeutics Corp. announced its intention to issue common shares to satisfy the accrued interest on its secured convertible notes as part of its private placement financing. This move, consistent with previous quarters, involves issuing 430,930 common shares at a price of $0.22 per share to cover $94,806.23 of accrued interest, reflecting the company’s commitment to structured financial strategies and stakeholder engagement.